18F FES-PET/MRI for Tailoring Treatment of Luminal A and Lobular Breast Cancer
Breast Cancer FemaleLobular Breast Carcinoma3 moreStudy hypothesis is that combining the advantages of hybrid PET/MRI and the high sensitivity/specificity of 16-alpha-18F-fluoro-17-beta-estradiol(FES), a radiolabeled form of estrogen binding to functionally active ER, the investigators could obtain a reliable, non-invasive, operator-independent, one-stage imaging method for staging LumA and ER-positive Lobular tumours.
Impact of Dietary Inflammatory Potential on Breast Cancer Risk
Breast Atypical Ductal HyperplasiaBreast Atypical Lobular Hyperplasia3 moreThis study evaluates the association of dietary inflammatory potential with breast cancer risk. Information collected in this study may help doctors to identify modifiable risk factors, screen high risk patients early, improve prevention strategies, and provide timely intervention for early therapeutic management as needed.
Improving Survival for Metastatic Lobular Breast Cancer (PLUMB Registry)
Metastatic Breast CancerLobular Breast CarcinomaThis is a prospective observational registry for patients with invasive lobular carcinoma (ILC) of the breast. After the first 1cohort is enrolled, the collected data will be utilized to develop an ILC specific response assessment tool.
Caloric Restriction in Treating Patients With Stage 0-I Breast Cancer Undergoing Surgery and Radiation...
Ductal Breast Carcinoma in SituInvasive Ductal Breast Carcinoma5 moreThis pilot clinical trial studies caloric restriction in patients with stage 0-I breast cancer during surgery and radiation therapy. Reducing caloric intake may prevent disease progression in patients with breast cancer. Radiation therapy uses high energy x rays to kill tumor cells. Giving dietary intervention and radiation therapy together may kill more tumor cells.
Accelerated Radiation Therapy After Surgery in Treating Patients With Breast Cancer
Inflammatory Breast CancerInvasive Ductal Breast Carcinoma8 moreThis phase II trial studies how well giving accelerated radiation therapy (RT) after surgery works in treating patients with breast cancer. RT uses high energy x rays to kill tumor cells. Giving RT after surgery may kill any remaining tumor cells
Single Fraction Intraoperative Radiotherapy
Invasive Ductal and Invasive Lobular Breast CarcinomaStage 0 Breast Carcinoma2 moreThis clinical trial is being conducted to find out the effects (good and bad) of giving the full radiation treatment for breast cancer as a single dose of radiation during surgery for breast cancer. This single fraction intraoperative radiotherapy with electrons will study the toxicity, local control and cosmetic outcome.
Hormone Therapy Or Chemotherapy Before Surgery Based on Gene Expression Analysis in Treating Patients...
Ductal Breast Carcinoma in SituLobular Breast Carcinoma in Situ5 moreThis randomized pilot clinical trial studied whether the Oncotype DX gene expression "Recurrence Score" (RS) would be useful for helping make a decision about which type of pre-operative treatment, hormone therapy or chemotherapy would be a better for patients with hormone responsive cancers that were not suitable for breast conserving surgery. The RS is currently used to predict the risk of distant recurrence and the benefit of the addition of chemotherapy to hormonal therapy in the adjuvant setting.
Omega-3 Fatty Acid in Treating Patients With Stage I-III Breast Cancer
Ductal Breast Carcinoma in SituLobular Breast Carcinoma in Situ7 moreThis phase II clinical trial studies how well omega-3 fatty acid works in treating patients with stage I-III breast cancer. Studying samples of tissue and blood in the laboratory from breast cancer patients receiving omega-3 fatty acid may help doctors learn more about the effects of omega-3 fatty acid on tumor cells.
Using Clinicopathomic Markers to Predict Neoadjuvant Chemotherapy Response in Breast Cancer
Breast CancerInvasive Ductal Breast Carcinoma1 moreThis study examines retrospective clinical data on patients diagnosed with breast cancer and monitor their response to neoadjuvant chemotherapy, incidence of locoregional recurrence, distant metastasis, and disease-free survival. The hypothesis of this study is that breast cancer patients who achieve a pathological complete response (pCR) to neoadjuvant chemotherapy demonstrate distinct clinicopathomic biomarker signatures.
CDH1 Germline Mutations in Lobular Breast Cancer
Lobular Breast CarcinomaCDH1 Gene InactivationInvasive lobular breast carcinoma (ILBC) represents 5-15% of all invasive BCs. The CDH1 gene (OMIM no. 192090), located on the chromosome 16q22.1, encodes for the E-cadherin protein, a key regulator of cell adhesion. Loss of E-cadherin expression is frequently detected in LBC CDH1 germline loss-of-function mutations are associated with the autosomal dominant cancer-predisposition syndrome, hereditary diffuse gastric cancer (HDGC; OMIM no. 137215). The cumulative risk of LBC for women with a CDH1 mutation is estimated to be 42% (95% CI 23% to 68%) by 80 years, when it is a component of HDGC syndrome. Recently, some authors described CDH1 germline mutations in women with in situ or ILBC with early onset (<45 or <50) and bilateral in situ or ILBC with no family history of HDGC. These results are opening a new scenario, suggesting that CDH1 could be a susceptibility gene for LBC in women without a family history of DGC. The first aim of this study is to investigate prevalence of CDH1 in this specific population of women with early onset (<45 or <50) in situ or ILBC, bilateral LBC or LBC with no family history of HDGC.